Please introduce yourself and give a little background of your current activities?

My name is Romain Daillère, co-founder of EverImmune and acting as scientific director of the company, devoted to treating cancer patients with live biotherapeutic products for oral adjuvants to anticancer treatments.

 What is the most exciting areas of gut microbiome you are currently working on?

We are focusing on immuno-oncology. We are harnessing the potential of the gut microbiota for the development of diagnosis and therapeutic tools.

Please introduce yourself and give a little background of your current activities?

My name is Romain Daillère, co-founder of EverImmune and acting as scientific director of the company, devoted to treating cancer patients with live biotherapeutic products for oral adjuvants to anticancer treatments.

 What is the most exciting areas of gut microbiome you are currently working on?

We are focusing on immuno-oncology. We are harnessing the potential of the gut microbiota for the development of diagnosis and therapeutic tools.

On July 6-7, Microbiome Connect brought together 250 industry experts, innovative researchers and clinical leaders in Amsterdam for the eighth annual Microbiome Connect: Europe. Across the two days, a key area of discussion focussed on gaining a more detailed picture of complex microbial communities. We sat down with Brice Le Francois, Senior R&D Manager, DNA Genotek to shed some light on the critical role of metatranscriptomics to characterise microbiome functionality.